FDA Rejects Bulevirtide for Hepatitis D FDA Rejects Bulevirtide for Hepatitis D

The FDA cited concerns over the production and delivery of bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor that received conditional approved in Europe in 2020.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news